Skip to main content
main-content

24-10-2018 | Systemic lupus erythematosus | ACR/ARHP 2018 | Video

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

EULAR 2020 E-Congress hub

Access the latest news and expert video commentary from the EULAR 2020 E-Congress.

Image Credits